Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

NCT02815033 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

DRUG: Enzalutamide
PROCEDURE: 11C or 18F-Choline PET/CT
PROCEDURE: Whole body MRI
PROCEDURE: Bone scan

Sponsor

The European Uro-Oncology Group

Collaborators

[object Object]